EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results

Giovanni Scambia iD, Ricardo Villalobos Valencia iD, Nicoletta Colombo iD, David Cibula iD, Charles A Leath iD, Mariusz Bidziński, Jae-Weon Kim iD, Joo Hyun Nam, Radoslaw Madry iD, Carlos Hernández, Paulo A R Mora iD, Sang Young Ryu und 5 weitere

Journal of Clinical Oncology · 20.04.2025 · 43 (12) · 1408-1416

DOI: 10.1200/jco.24.00933 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.04.2025. Verfasst von Giovanni Scambia und 16 weiteren Autor:innen. Beteiligte Einrichtung: Università Cattolica del Sacro Cuore-Fondazione Policlinico A. Gemelli, IRCCS, Rome, Italy. Hauptthemen laut MEDLINE: Phthalazines, Piperazines, Ovarian Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Olaparib treatment significantly improved objective response rate (primary end point) and progression-free survival versus nonplatinum chemotherapy in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer in the open-label phase III SOLO3 trial (ClinicalTrials.gov identifier: NCT02282020 ). We report final overall survival (OS; prespecified secondary end point), post hoc OS analysis by number of previous chemotherapy lines, and exploratory BRCA reversion mutation analysis. Two hundred sixty-six patients were randomly assigned 2:1 to olaparib tablets (300 mg twice daily; n = 178) or physician's choice of single-agent nonplatinum chemotherapy (pegylated liposomal doxorubicin, paclitaxel, gemcitabine, or topotecan; n = 88). OS was similar with olaparib versus chemotherapy (hazard ratio [HR], 1.07 [95% CI, 0.76 to 1.49]; P = .71, median 34.9 and 32.9 months, respectively, full analysis set). OS with olaparib was favorable in patients with two previous chemotherapy lines (HR, 0.83 [olaparib v chemotherapy] [95% CI, 0.51 to 1.38]; median 37.9 v 28.8 months); however, a potential detrimental effect was seen in patients with at least three previous chemotherapy lines (HR, 1.33 [95% CI, 0.84 to 2.18]; median 29.9 v 39.4 months). BRCA reversion mutations might have contributed to this finding. No patient randomly assigned to olaparib with a BRCA reversion mutation detected at baseline (6 of 170 [3.5%]) achieved an objective tumor response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhthalazinesPiperazinesOvarian NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsNeoplasm Recurrence, LocalPoly(ADP-ribose) Polymerase InhibitorsHumansFemaleMiddle AgedAgedAdultPaclitaxelProgression-Free SurvivalDoxorubicinTopotecanDeoxycytidineGemcitabinePolyethylene GlycolsBRCA1 ProteinBRCA2 Protein

Substanzen

olaparibPhthalazinesPiperazinesPaclitaxelDoxorubicinliposomal doxorubicinTopotecanDeoxycytidinePoly(ADP-ribose) Polymerase InhibitorsGemcitabine

Autor:innen und Institutionen

  • Università Cattolica del Sacro Cuore-Fondazione Policlinico A. Gemelli, IRCCS, Rome, Italy.
  • Centro Medico Dalinde, Mexico City, Mexico.
  • Department of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy.
  • Gynecologic Oncology Program European Institute of Oncology IRCCS, Milan, Italy.
  • Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
  • O'Neal Comprehensive Cancer Center, University of Alabama, Birmingham, AL.

ORCID-Profile: Giovanni Scambia, Ricardo Villalobos Valencia, Nicoletta Colombo, David Cibula, Charles A Leath, Jae-Weon Kim, Radoslaw Madry, Paulo A R Mora, Natalia Lukashchuk, Richard T Penson

Förderung

  • NCI NIH HHS

Zitieren

APA

Scambia, G., Villalobos Valencia, R., Colombo, N., Cibula, D., Leath, C. A., Bidziński, M., Kim, J. W., Nam, J. H., Madry, R., Hernández, C., Mora, P. A. R., Ryu, S. Y., Ah-See, M. L., Lowe, E. S., Lukashchuk, N., Carter, D., & Penson, R. T. (2025). Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results. Journal of Clinical Oncology, 43(12), 1408-1416. https://doi.org/10.1200/jco.24.00933

Vancouver

Scambia G, Villalobos Valencia R, Colombo N, Cibula D, Leath CA, Bidziński M, et al. Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results. Journal of Clinical Oncology. 2025;43(12):1408-1416. doi:10.1200/jco.24.00933

BibTeX
@article{Scambia2025,
  author = {Scambia, Giovanni and Villalobos Valencia, Ricardo and Colombo, Nicoletta and Cibula, David and Leath, Charles A and Bidziński, Mariusz and Kim, Jae-Weon and Nam, Joo Hyun and Madry, Radoslaw and Hernández, Carlos and Mora, Paulo A R and Ryu, Sang Young and Ah-See, Mei-Lin and Lowe, Elizabeth S and Lukashchuk, Natalia and Carter, Dave and Penson, Richard T},
  title = {Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {12},
  pages = {1408--1416},
  doi = {10.1200/jco.24.00933}
}
Kostenlos starten →